Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: June 26, 2017
Which drugs does patent 8,920,383 protect, and when does it expire?
| Title: | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
| Abstract: | A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device comprises a threaded piston rod, a limiter and a driver. The three elements are arranged such that during dose setting, the limiter is moved towards an end-of-contend position, wherein dose setting is limited. The invention comprises an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for prevention ejection of a dose exceeding the set dose. |
| Inventor(s): | Enggaard; Christian Peter (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 11/996,409 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk Inc | RYZODEG 70/30 | insulin aspart; insulin degludec | SOLUTION;SUBCUTANEOUS | 203313-001 | Sep 25, 2015 | RX | Yes | Yes | 8,920,383 | ► Subscribe | Y | ||||||||||||||||||
Novo Nordisk Inc | TRESIBA | insulin degludec | SOLUTION;SUBCUTANEOUS | 203314-001 | Sep 25, 2015 | RX | Yes | No | 8,920,383 | ► Subscribe | Y | ||||||||||||||||||
Novo Nordisk Inc | TRESIBA | insulin degludec | SOLUTION;SUBCUTANEOUS | 203314-002 | Sep 25, 2015 | RX | Yes | Yes | 8,920,383 | ► Subscribe | Y | ||||||||||||||||||
Novo Nordisk Inc | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | 8,920,383 | ► Subscribe | Y | ||||||||||||||||||
Novo Nordisk Inc | LEVEMIR FLEXTOUCH | insulin detemir recombinant | INJECTABLE;SUBCUTANEOUS | 021536-005 | Oct 31, 2013 | RX | Yes | Yes | 8,920,383 | ► Subscribe | Y | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05016291 | Jul 27, 2005 | |
| PCT Information | |||
| PCT Filed | July 17, 2006 | PCT Application Number: | PCT/EP2006/007004 |
| PCT Publication Date: | February 15, 2007 | PCT Publication Number: | WO2007/017052 |
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 499962 | ► Subscribe | |||||||||||||||||||||||||||
| China | 101227943 | ► Subscribe | |||||||||||||||||||||||||||
| Germany | 602006020453 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1909870 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1909870 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
Join the 21,698 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
